Does the media favor EWTX or XNCR?

In the previous week, Xencor had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 7 mentions for Xencor and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.73 beat Xencor's score of 0.65 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XNCR or ACAD?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Xencor. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 7 mentions for Xencor. ACADIA Pharmaceuticals' average media sentiment score of 0.94 beat Xencor's score of 0.65 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, TNGX or XNCR?

Xencor has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tango Therapeutics $62.38M 65.76 -$101.59M -$0.83 N/A Xencor $125.58M 8.83 -$91.92M -$2.29 N/A

Does the media prefer TNGX or XNCR?

In the previous week, Xencor had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 7 mentions for Xencor and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.57 beat Xencor's score of 0.65 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Xencor 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, XNCR or NAMS?

Xencor has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 8.83 -$91.92M -$2.29 N/A NewAmsterdam Pharma $22.50M 172.91 -$203.82M -$1.79 N/A

Does the media favor XNCR or NAMS?

In the previous week, Xencor had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Xencor and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Xencor's score of 0.65 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNLI or XNCR?

In the previous week, Denali Therapeutics had 4 more articles in the media than Xencor. MarketBeat recorded 11 mentions for Denali Therapeutics and 7 mentions for Xencor. Denali Therapeutics' average media sentiment score of 0.78 beat Xencor's score of 0.65 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Xencor (XNCR) Competitors

$14.96 -0.89 (-5.62%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$14.96 0.00 (0.00%)

As of 07/13/2026 06:18 PM Eastern

Compare

XNCR vs. EWTX, ACAD, TNGX, NAMS, and DNLI

Should you buy Xencor stock or one of its competitors? MarketBeat compares Xencor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xencor include Edgewise Therapeutics (EWTX), ACADIA Pharmaceuticals (ACAD), Tango Therapeutics (TNGX), NewAmsterdam Pharma (NAMS), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

How does Xencor compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Xencor has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Xencor	$125.58M	8.83	-$91.92M	-$2.29	N/A

In the previous week, Xencor had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 7 mentions for Xencor and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.73 beat Xencor's score of 0.65 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Xencor	-177.10%	-28.77%	-20.52%

Edgewise Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Xencor has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Edgewise Therapeutics presently has a consensus price target of $47.92, suggesting a potential upside of 16.11%. Xencor has a consensus price target of $24.25, suggesting a potential upside of 62.10%. Given Xencor's higher probable upside, analysts clearly believe Xencor is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Xencor beats Edgewise Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Xencor compare to ACADIA Pharmaceuticals?

Xencor (NASDAQ:XNCR) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Xencor's net margin of -177.10%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Xencor currently has a consensus target price of $24.25, suggesting a potential upside of 62.10%. ACADIA Pharmaceuticals has a consensus target price of $32.94, suggesting a potential upside of 29.18%. Given Xencor's higher probable upside, research analysts clearly believe Xencor is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Xencor has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.83	-$91.92M	-$2.29	N/A
ACADIA Pharmaceuticals	$1.07B	4.08	$391M	$2.20	11.59

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Xencor. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 7 mentions for Xencor. ACADIA Pharmaceuticals' average media sentiment score of 0.94 beat Xencor's score of 0.65 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats Xencor on 13 of the 16 factors compared between the two stocks.

How does Xencor compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Xencor has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	65.76	-$101.59M	-$0.83	N/A
Xencor	$125.58M	8.83	-$91.92M	-$2.29	N/A

In the previous week, Xencor had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 7 mentions for Xencor and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.57 beat Xencor's score of 0.65 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Tango Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 5.1% of Xencor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tango Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Xencor has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Xencor	-177.10%	-28.77%	-20.52%

Tango Therapeutics currently has a consensus target price of $41.50, suggesting a potential upside of 46.33%. Xencor has a consensus target price of $24.25, suggesting a potential upside of 62.10%. Given Xencor's higher possible upside, analysts plainly believe Xencor is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Tango Therapeutics beats Xencor on 9 of the 16 factors compared between the two stocks.

How does Xencor compare to NewAmsterdam Pharma?

Xencor (NASDAQ:XNCR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Xencor has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.83	-$91.92M	-$2.29	N/A
NewAmsterdam Pharma	$22.50M	172.91	-$203.82M	-$1.79	N/A

Xencor has a net margin of -177.10% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

In the previous week, Xencor had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Xencor and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Xencor's score of 0.65 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor currently has a consensus target price of $24.25, suggesting a potential upside of 62.10%. NewAmsterdam Pharma has a consensus target price of $49.00, suggesting a potential upside of 47.24%. Given Xencor's higher probable upside, equities research analysts plainly believe Xencor is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Xencor has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Xencor on 9 of the 17 factors compared between the two stocks.

How does Xencor compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Xencor has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.71	-$512.54M	-$2.88	N/A
Xencor	$125.58M	8.83	-$91.92M	-$2.29	N/A

92.9% of Denali Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Denali Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Xencor has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Xencor	-177.10%	-28.77%	-20.52%

Denali Therapeutics presently has a consensus price target of $34.75, indicating a potential upside of 31.23%. Xencor has a consensus price target of $24.25, indicating a potential upside of 62.10%. Given Xencor's higher possible upside, analysts plainly believe Xencor is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Denali Therapeutics had 4 more articles in the media than Xencor. MarketBeat recorded 11 mentions for Denali Therapeutics and 7 mentions for Xencor. Denali Therapeutics' average media sentiment score of 0.78 beat Xencor's score of 0.65 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Denali Therapeutics beats Xencor on 11 of the 17 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XNCR vs. The Competition

Export

Metric	Xencor	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.18B	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-6.53	19.17	27.11	24.26
Price / Sales	8.83	838.79	587.92	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	1.68	4.22	10.75	6.29
Net Income	-$91.92M	$64.26M	$3.58B	$330.66M
7 Day Performance	-4.53%	-3.58%	-2.06%	-1.32%
1 Month Performance	21.33%	2.12%	3.32%	-0.64%
1 Year Performance	69.04%	20.35%	26.36%	19.08%

Xencor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XNCR Xencor	2.2313 of 5 stars	$14.96 -5.6%	$24.25 +62.1%	+69.4%	$1.18B	$125.58M	N/A	280	News Coverage
EWTX Edgewise Therapeutics	2.3022 of 5 stars	$41.71 +4.0%	$47.64 +14.2%	+198.2%	$4.47B	N/A	N/A	60	News Coverage
ACAD ACADIA Pharmaceuticals	4.8196 of 5 stars	$25.90 +0.5%	$32.59 +25.8%	+21.5%	$4.43B	$1.07B	11.76	510
TNGX Tango Therapeutics	2.9573 of 5 stars	$29.75 -0.6%	$41.50 +39.5%	+378.2%	$4.30B	$56.99M	N/A	90	Positive News
NAMS NewAmsterdam Pharma	3.3734 of 5 stars	$35.49 +1.7%	$49.00 +38.1%	+54.5%	$4.15B	$22.57M	N/A	4	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XNCR) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xencor (XNCR) Competitors

XNCR vs. EWTX, ACAD, TNGX, NAMS, and DNLI

How does Xencor compare to Edgewise Therapeutics?

Summary

How does Xencor compare to ACADIA Pharmaceuticals?

Summary

How does Xencor compare to Tango Therapeutics?

Summary

How does Xencor compare to NewAmsterdam Pharma?

Summary

How does Xencor compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xencor (XNCR) Competitors

XNCR vs. EWTX, ACAD, TNGX, NAMS, and DNLI

How does Xencor compare to Edgewise Therapeutics?

Which has stronger earnings & valuation, EWTX or XNCR?

Does the media favor EWTX or XNCR?

Is EWTX or XNCR more profitable?

Which has more risk & volatility, EWTX or XNCR?

Do analysts prefer EWTX or XNCR?

Summary

How does Xencor compare to ACADIA Pharmaceuticals?

Is XNCR or ACAD more profitable?

Do analysts recommend XNCR or ACAD?

Do institutionals and insiders hold more shares of XNCR or ACAD?

Which has more risk and volatility, XNCR or ACAD?

Which has stronger valuation & earnings, XNCR or ACAD?

Does the media refer more to XNCR or ACAD?

Summary

How does Xencor compare to Tango Therapeutics?

Which has higher valuation and earnings, TNGX or XNCR?

Does the media prefer TNGX or XNCR?

Do insiders & institutionals hold more shares of TNGX or XNCR?

Which has more volatility & risk, TNGX or XNCR?

Is TNGX or XNCR more profitable?

Do analysts prefer TNGX or XNCR?

Summary

How does Xencor compare to NewAmsterdam Pharma?

Which has higher earnings and valuation, XNCR or NAMS?

Is XNCR or NAMS more profitable?

Does the media favor XNCR or NAMS?

Do analysts prefer XNCR or NAMS?

Which has more risk and volatility, XNCR or NAMS?

Do institutionals and insiders believe in XNCR or NAMS?

Summary

How does Xencor compare to Denali Therapeutics?

Which has preferable valuation and earnings, DNLI or XNCR?

Do institutionals and insiders believe in DNLI or XNCR?

Which has more volatility & risk, DNLI or XNCR?

Is DNLI or XNCR more profitable?

Do analysts rate DNLI or XNCR?

Does the media refer more to DNLI or XNCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools